Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids
Public ClinicalTrials.gov record NCT01090024. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Placebo-controlled, Efficacy and Safety Cross-over Study of 4 Weeks of Oral BI 671800 ED 200 mg Twice Daily or 400 mg Once Daily Administered in the Morning (AM) or Evening (PM), in Symptomatic Asthma Patients on Inhaled Fluticasone Propionate MDI
Study identification
- NCT ID
- NCT01090024
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 108 participants
Conditions and interventions
Conditions
Interventions
- BI 671800 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2010
- Primary completion
- Jan 31, 2011
- Completion
- Feb 17, 2011
- Last update posted
- May 10, 2022
2010 – 2011
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1268.53.01013 Boehringer Ingelheim Investigational Site | Huntington Beach | California | — | — |
| 1268.53.01014 Boehringer Ingelheim Investigational Site | Mission Viejo | California | — | — |
| 1268.53.01002 Boehringer Ingelheim Investigational Site | Stockton | California | — | — |
| 1268.53.01009 Boehringer Ingelheim Investigational Site | Colorado Springs | Colorado | — | — |
| 1268.53.01011 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 1268.53.01001 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1268.53.01005 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 1268.53.01006 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1268.53.01007 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1268.53.01010 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1268.53.01003 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1268.53.01008 Boehringer Ingelheim Investigational Site | El Paso | Texas | — | — |
| 1268.53.01012 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1268.53.01015 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01090024, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 10, 2022 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01090024 live on ClinicalTrials.gov.